Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HRS-5041 by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval
HRS-5041 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Prostate Cancer. According to GlobalData,...